HNRNPA2B1 and Miyoshi myopathy: In 2021, Jiang et al. [138] concluded that HNRNPA2B1 is highly expressed in MM patients and mediates m6A methylation modification of ILF3 mRNA, thereby contributing to the proliferation of MM cells in vitro and in vivo, which results in MM patients presenting a poor prognosis; conversely, genetic depletion of HNRNPA2B1 inhibits the growth of tumor cells and exerts an anti-cancer effect.